SRR934732
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.039421813403415
- age_years
- 55
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.539
- ANGIOGENESIS+0.532
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- G2M_CHECKPOINT+0.466
- MYC_TARGETS_V1+0.449
- TNFA_SIGNALING_VIA_NFKB+0.428
- COAGULATION+0.331
- ALLOGRAFT_REJECTION+0.290
- IL6_JAK_STAT3_SIGNALING+0.259
- MYC_TARGETS_V2+0.244
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.341
- HEME_METABOLISM-0.310
- PEROXISOME-0.280
- ADIPOGENESIS-0.258
- ESTROGEN_RESPONSE_EARLY-0.252
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.227
- BILE_ACID_METABOLISM-0.212
- PANCREAS_BETA_CELLS-0.199
- OXIDATIVE_PHOSPHORYLATION-0.195
- FATTY_ACID_METABOLISM-0.186
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.840 |
| 2 | TCGA-CQ-A4CB-01A-11R-A24Z-07 | — | — | 0.816 |
| 3 | F5EB77B4-61AD-40EC-B5B0-44D2D5AD66D7 | — | — | 0.806 |
| 4 | 333376 | EPN | Supratentorial EPN | 0.778 |
| 5 | X63da1fd8.ca5b.494f.8625.4daf5f898f53 | — | cohortA1 | 0.776 |
| 6 | BS_84XCR9GG | high-grade glioma | — | 0.775 |
| 7 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.773 |
| 8 | BS_DHA5FMVW | ATRT | — | 0.753 |
| 9 | SRR8943028 | — | — | 0.739 |
| 10 | SRR23036891 | — | — | 0.735 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.539 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.532 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.466 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.449 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.428 | Inavolisib | — uncovered |
| COAGULATION | 0.331 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.259 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.244 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.233 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.185 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.142 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.142 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.139 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.137 | Idelalisib | — uncovered |
| APOPTOSIS | 0.104 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.092 | Inavolisib | — uncovered |